September 06, 2021 Another gene therapy safety scare hits The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
July 13, 2021 Novo bets against Crispr for amyloidosis Novo moves into amyloidosis not long after Intellia made a splash here.
March 23, 2021 The Huntington’s pipeline takes a blow The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.